<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561571</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0326</org_study_id>
    <nct_id>NCT03561571</nct_id>
  </id_info>
  <brief_title>Triglyceride Rich Lipoproteins and Platelet Activation in Type 2 Diabetes</brief_title>
  <acronym>COMPLETE</acronym>
  <official_title>Composition of Triglyceride Rich Lipoproteins and Platelet Activation in Type 2 Diabetic Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate in vitro the effect of triglyceride rich lipoproteins (TGRL) obtained in type
      2 diabetic women in the fasting state and following a randomized isocaloric lipid rich
      breakfast on control human platelets

      Randomized Comparison of butter versus chocolate spread in 2 groups of 15 patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Actual">May 14, 2019</completion_date>
  <primary_completion_date type="Actual">May 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting thromboxane B2 concentration</measure>
    <time_frame>Hour 0</time_frame>
    <description>ex vivo experiment : TGRL obtained by preparative Unesterified cholesterol (UC) incubated with control human platelets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>after breakfast thromboxane B2 concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>ex vivo experiment : TGRL obtained by preparative Unesterified cholesterol (UC) incubated with control human platelets</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measurement of fasting platelet activation by turbidimetric method</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of post prandial platelet activation by turbidimetric method</measure>
    <time_frame>4 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting lipidomic composition of triglyceride rich lipoproteins</measure>
    <time_frame>Hour 0</time_frame>
    <description>Characterization and comparison of LRT lipidomics in fasting DT2 patients and following the ingestion of a high-fat breakfast according to their source (short and medium chain fatty acids (butter) versus palmitic acid (palm oil present in spreads).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post prandial lipidomic composition of triglyceride rich lipoproteins</measure>
    <time_frame>4 Hours</time_frame>
    <description>Characterization and comparison of LRT lipidomics in fasting DT2 patients and following the ingestion of a high-fat breakfast according to their source (short and medium chain fatty acids (butter) versus palmitic acid (palm oil present in spreads).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Butter based breakfast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chocolate spread based breakfast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>butter based breakfast</intervention_name>
    <description>ingestion of proteins : 5 g, lipids 20 g, glucides 57 g</description>
    <arm_group_label>Butter based breakfast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chocolate spread based breakfast</intervention_name>
    <description>ingestion of proteins 7 g, lipids 20 g, glucides 56 g</description>
    <arm_group_label>Chocolate spread based breakfast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Menopausal women

          -  HbA1c ≥6,5 ou ≤10%

          -  27 ≤ BMI ≤40 kg/m2

        Exclusion Criteria:

          -  Insulin therapy

          -  fibrates or Omega 3 fatty acids supplements

          -  Hormonal replacement therapy of menopause

          -  Glycemia &gt; 16 mmol/l

          -  Alcohol abuse (≥3 Unit/day)

          -  Special dietary habits

          -  History of bariatric surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Louis Pradel - department of endocrinology</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chylomicrons</keyword>
  <keyword>Very Low Density Lipoprotein</keyword>
  <keyword>saturated fat</keyword>
  <keyword>platelet function</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>post prandial phase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

